TheranosticTrials.org

Clinical Trial · NCT03542773

Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET

Overview

To use 18F-DCFPyL imaging agent and PET/CT to detect none prostate cancer solid malignancies and schwannoma tumors.

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase

Phase 1

Contacts

Steven Rowe, M.D., Ph.D (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03542773

Drug / Compound

DCFPyL

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Biopsy-proven cancer or Schwannoma diagnosis
  • No contraindications to PET scanning to include pregnancy, etc. For females of childbearing potential, negative serum pregnancy test obtained within a 10-day period prior to PET study

Exclusion

  • In female subjects pregnancy.
  • Administered a radioisotope within 5 physical half-lives prior to PET imaging